Evidence map›Paper›PMID 36824780›Full record

ArticlebioRxiv : the preprint server for biology2023

Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer Therapy.

Ella N Hoogenboezem, Shrusti S Patel, Ashley B Cavnar, Justin H Lo, Lauren M Babb, Nora Francini, Prarthana Patil, Juan M Colazo, Danielle L Michell, Violeta M Sanchez and 11 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Ella N HoogenboezemDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Shrusti S PatelDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Ashley B CavnarDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Justin H LoDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Lauren M BabbDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Nora FranciniDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Prarthana PatilDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Juan M ColazoDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Danielle L MichellDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Violeta M SanchezDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Joshua T McCuneDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Jinqi MaDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Carlisle R DeJuliusDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Linus H LeeDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Jonah C RoschDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN.
Ryan M AllenDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Larry D StokesDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Jordan L HillDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Kasey C VickersDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Rebecca S CookDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Craig L DuvallDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN.
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

Substrate Mediated siRNA Delivery from Scaffolds to Promote Wound RepairR01EB019409 · NIBIB · VANDERBILT UNIVERSITY · PI Craig Lewis Duvall · 2014 to 2026
$4.0M
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted TherapyR01CA260958 · NCI · VANDERBILT UNIVERSITY · PI COOK, REBECCA SARA, DUVALL, CRAIG LEWIS · 2021 to 2025
$3.0M
VOLT (Vanderbilt Oncology Training Program)T32CA217834 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Douglas B Johnson · 2018 to 2026
$2.7M
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 BlockadeR01CA224241 · NCI · VANDERBILT UNIVERSITY · PI BRANTLEY-SIEDERS, DANA M, COOK, REBECCA SARA · 2018 to 2022
$2.5M
Albumin Binding siRNAs for Systemic Treatment of Multi-Joint OsteoarthritisR21AR078636 · NIAMS · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2021 to 2022
$374k
Albumin-binding nanocomplexes for delivery of combination siRNA therapeutics to KRAS-driven cholangiocarcinomaF32CA268705 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LO, JUSTIN HAN-JE · 2022 to 2022
$76k
NCI NIH HHS F32 CA268705NCI NIH HHS R01 CA224241NCI NIH HHS R01 CA260958NCI NIH HHS T32 CA217834NIAMS NIH HHS R21 AR078636NIBIB NIH HHS R01 EB019409
6 · The paper itself

Abstract

The high potential for therapeutic application of siRNAs to silence traditionally undruggable oncogenic drivers remains largely untapped due to the challenges of tumor cell delivery. Here, siRNAs were optimized for

Identifiers

PMID36824780
PMCPMC9948981
OpenAlexW4320913577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.